Targeted OncologyEngineering Chimeric Antigen Receptor T Cells to Treat GlioblastomaTargeted OncologyChimeric antigen receptors (CARs) are specialized molecules that can be expressed on the surface of T cells, allowing for redirected cytotoxicity again… Continue reading
|
Blastic Plasmacytoid Dendritic Neoplasm Study Begins for CAR T-Cell Candidate
Rare Disease Report Cellectis announced today that the Phase 1 clinical study testing their CAR T-cell therapy, UCART123, to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) at the MD Anderson Cancer Center has begun, and the first patient was given the drug. Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR–T TherapyGenetic Engineering & Biotechnology News (blog) |
NBCNews.com |
Scientists Find New Way to ‘Print’ Living Tissue
NBCNews.com To avoid this, the Oxford team, led by 3D-bioprinting scientist Alexander Graham from Oxford Synthetic Biology (OxSyBio), contained their cells within nanolitre droplets that were wrapped in a lipid coating. These droplets could then be placed one … Scientists 3D-print ‘high-resolution’ living tissueRT Oxford scientists develop new method to 3D print ‘high resolution’ living tissuesInternational Business Times UK |
NBCNews.com |
Scientists Find New Way to ‘Print’ Living Tissue
NBCNews.com To avoid this, the Oxford team, led by 3D-bioprinting scientist Alexander Graham from Oxford Synthetic Biology (OxSyBio), contained their cells within nanolitre droplets that were wrapped in a lipid coating. These droplets could then be placed one … Scientists 3D-print ‘high-resolution’ living tissueRT Oxford scientists develop new method to 3D print ‘high resolution’ living tissuesInternational Business Times UK |
|
Monsanto, ToolGen enter Crispr licensing pact
World Grain ST. LOUIS, MISSOURI, U.S. — Monsanto Co. and ToolGen, Inc., a Seoul, South Korea-based biotechnology company specializing in genome editing, have reached a global licensing agreement for the use of ToolGen’s Crispr technology platform to develop … |